Navigation Links
Medicago initiates work on Swine Flu strain
Date:4/28/2009

QUEBEC CITY, April 28 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has received a genetic sequence of the new strain of influenza A (H1N1) that has recently been identified in USA and Mexico, and has commenced laboratory work with its VLP vaccine technology to produce material for testing. According to the World Health Organization ("WHO"), a genetic analysis shows this new flu strain is a never-before-seen mixture of swine, human and avian viruses and has the potential of becoming a pandemic. The Company has already expressed VLPs of the following pandemic strains in plants: Singapore (H2N2), Anhui (H5N1), Vietnam (H5N1), Hong Kong (H6N1 and H9N2), Equine/Prague (H7N7), and of the seasonal strains New Caledonia (H1N1), Solomon Island (H1N1) and Brisbane (H1N1). Medicago is keeping health authorities informed on its work.

Medicago's H5N1 pandemic VLP vaccine has shown to be immunogenic at doses as low as 5 micrograms in preclinical studies and provided 100% cross-protection to different strains of the H5N1 virus in an animal model. The Company's proprietary plant-based manufacturing technology could deliver a vaccine, just one month after the identification of the genetic sequence from an emerging pandemic strain. This vaccine would then be tested in animals and humans and reviewed by Health Canada before it is produced on a commercial scale. Medicago recently had a pre-Clinical Trial Application ("CTA") meeting with Health Canada's Biologics and Genetic Therapies Directorate ("BGTD"). Based on the outcome of the meeting, the Company is finalising pre-clinical studies and preparing to move ahead with the submission of a CTA for its lead H5N1 pandemic VLP vaccine and with final approval will initiate a Phase I clinical trial in the third quarter of 2009.

About Medicago

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward Looking Statements

This press release contains forward-looking statements which reflect Medicago's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. Medicago disclaims any obligation to update these forward-looking statements.

    Neither TSX Venture Exchange nor its Regulation Services Provider (as
    that term is defined in the policies of the TSX Venture Exchange) accepts
    responsibility for the adequacy or accuracy of this release


'/>"/>
SOURCE Medicago Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
3. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
4. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
5. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
6. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
7. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
8. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
9. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
10. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
11. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin ... may offer a new way to treat the disease. Surviving Mesothelioma has just posted ... , Scientists from several Korean institutions based their mesothelioma study on the fact the ...
(Date:5/19/2016)... RIDGE, British Columbia , May 19, 2016 ... AdvanTec Global Innovations Inc. (AGI), based out of ... recently added Greenlane Biogas Ltd. to its existing ... 2-year contract manufacturing agreement. AFS along with its ... Technologies (ABT) is a vertically integrated industrial group ...
(Date:5/19/2016)... Regen BioPharma, Inc ... announced today initiation of a preclinical development program ... cancer immunotherapeutic product leveraging its NR2F6 immunological checkpoint. ... generation of cord blood derived killer cells whose ... product in development will be a "universal donor" ...
(Date:5/18/2016)... ... May 18, 2016 , ... Shimadzu Scientific Instruments announces ... of Toledo. This two-day camp will take place annually starting June 2016. It ... pharmaceutical sciences in preparation for a university academic program. , The laboratory- ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
(Date:3/21/2016)... Unique technology combines v ... security   Xura, Inc. ... digital communications services, today announced it is working alongside ... customers, particularly those in the Financial Services Sector, the ... within a mobile app, alongside, and in combination with, ...
Breaking Biology News(10 mins):